Stocks
CymaBay Therapeutics, Inc.CBAY
NASDAQHealthcareBiotechnology$32.48+0.03%
Price as of · delayed, not real-time
Focused on developing and commercializing therapies for liver and other chronic diseases, this biopharmaceutical company is known for its investigational drug seladelpar, targeting primary biliary cholangitis. Investors closely monitor its clinical trial progress and regulatory milestones, as these factors significantly influence its valuation.
Market Cap: $3.7B52W Range: $7.26-$32.50
Congressional Interest in CymaBay Therapeutics, Inc. (CBAY)
1 member of Congress has disclosed 2 trades in CymaBay Therapeutics, Inc. (CBAY), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
1
Buys
1
Sells
1
Who in Congress Is Trading CBAY?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-07-19 | Roger W. Marshall | buy | $1K-$15K |
| 2017-07-19 | Roger W. Marshall | sell | $1K-$15K |